Eterna Therapeutics Inc. logo

Eterna Therapeutics Inc. (ERNA)

Market Closed
3 Jul, 17:00
NASDAQ (CM) NASDAQ (CM)
$
1. 99
+0.01
+0.25%
$
13.62M Market Cap
- P/E Ratio
0% Div Yield
1,164 Volume
0 Eps
$ 1.98
Previous Close
Day Range
1.97 2.04
Year Range
1.75 39.45
Want to track ERNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ERNA closed today higher at $1.99, an increase of 0.25% from yesterday's close, completing a monthly decrease of -42.46% or $1.47. Over the past 12 months, ERNA stock gained 520.31%.
ERNA is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Eterna Therapeutics Inc. has completed 4 stock splits, with the recent split occurring on Jun 12, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

ERNA Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs

Globenewswire | 1 week ago
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”

Globenewswire | 3 weeks ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes

Globenewswire | 1 month ago

Eterna Therapeutics Inc. Dividends

ERNA is not paying dividends to its shareholders.

Eterna Therapeutics Inc. Earnings

12 May 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
13 Aug 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS
ERNA is not paying dividends to its shareholders.
12 May 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
13 Aug 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS

Eterna Therapeutics Inc. (ERNA) FAQ

What is the stock price today?

The current price is $1.99.

On which exchange is it traded?

Eterna Therapeutics Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ERNA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 13.62M.

Has Eterna Therapeutics Inc. ever had a stock split?

Eterna Therapeutics Inc. had 4 splits and the recent split was on Jun 12, 2025.

Eterna Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Sanjeev Luther CEO
NASDAQ (CM) Exchange
114082308 Cusip
US Country
6 Employees
- Last Dividend
12 Jun 2025 Last Split
19 Oct 1992 IPO Date

Overview

Eterna Therapeutics Inc. is an innovative life science company, established in 2018 and headquartered in Cambridge, Massachusetts. Specializing in mRNA cell engineering technologies, Eterna is at the forefront of developing solutions for cell reprogramming and gene editing. Through a strategic license agreement with Factor Bioscience Limited, Eterna Therapeutics leverages cutting-edge research to pave the way for advancements in genetic therapies and biotechnology.

Products and Services

  • mRNA Cell Reprogramming and Gene Editing
  • This core technology offered by Eterna Therapeutics revolutionizes how scientists approach genetic manipulation, enabling precise alterations in the genetic makeup of cells. It is foundational for developing treatments for genetic disorders and advancing regenerative medicine.

  • NoveSlice and UltraSlice Gene-Editing Proteins
  • Eterna's proprietary gene-editing proteins, NoveSlice and UltraSlice, represent groundbreaking tools in the field of genome editing. These proteins allow for highly efficient and targeted modifications of DNA, providing a robust platform for therapeutic development and biomedical research.

  • ToRNAdo mRNA Delivery System
  • The ToRNAdo mRNA Delivery System is a state-of-the-art technology developed by Eterna for the efficient delivery of mRNA therapeutics. This system ensures that mRNA can be delivered to target cells with high efficacy, a crucial aspect for the success of mRNA-based therapies.

Contact Information

Address: 10355 Science Center Drive
Phone: 212 582 1199